Analysts Issue Forecasts for UTHR FY2026 Earnings

United Therapeutics Corporation (NASDAQ:UTHR) – Investment analysts at HC Wainwright issued their FY2026 EPS estimates for United Therapeutics in a research report issued to clients and investors on Monday, November 9th. HC Wainwright analyst M. Caufield forecasts that the biotechnology company will earn $27.46 per share for the year. HC Wainwright currently has a “Buy” rating and a $660.00 price objective on the stock. The consensus estimate for United Therapeutics’ current full-year earnings is $24.47 per share. HC Wainwright also issued estimates for United Therapeutics’ Q4 2026 earnings at $8.68 EPS, FY2027 earnings at $30.14 EPS, FY2028 earnings at $30.67 EPS, FY2029 earnings at $40.68 EPS and FY2030 earnings at $53.67 EPS.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported $5.71 EPS for the quarter, missing the consensus estimate of $6.01 by ($0.30). United Therapeutics had a net margin of 38.61% and a return on equity of 19.18%. The business had revenue of $832.50 million during the quarter, compared to analyst estimates of $781.14 million. During the same quarter in the prior year, the company earned $7.16 earnings per share. The firm’s revenue for the quarter was up 4.1% compared to the same quarter last year.

A number of other equities research analysts have also recently commented on UTHR. Cantor Fitzgerald reiterated an “overweight” rating and set a $850.00 target price on shares of United Therapeutics in a report on Monday, October 26th. Leerink Partners boosted their price target on United Therapeutics from $685.00 to $725.00 and gave the stock an “outperform” rating in a report on Monday, October 19th. Weiss Ratings downgraded United Therapeutics from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday. TD Cowen increased their price objective on United Therapeutics from $675.00 to $700.00 and gave the company a “buy” rating in a research note on Thursday, November 5th. Finally, The Goldman Sachs Group reiterated a “sell” rating and set a $368.00 price objective on shares of United Therapeutics in a research report on Thursday, October 15th. Twelve analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $676.40.

United Therapeutics Price Performance

Shares of United Therapeutics stock opened at $588.61 on Wednesday. United Therapeutics has a 1 year low of $449.58 and a 1 year high of $614.23. The business has a 50 day moving average price of $536.90 and a 200 day moving average price of $534.57. The company has a market capitalization of $25.07 billion, a P/E ratio of 22.21, a P/E/G ratio of 3.97 and a beta of 0.49.

United Therapeutics declared that its Board of Directors has approved a stock repurchase program on Thursday, October 22nd that authorizes the company to repurchase $2 billion in outstanding shares. This buyback authorization authorizes the biotechnology company to purchase up to 8.3% of its shares through open market purchases. Share buyback programs are generally an indication that the company’s board of directors believes its stock is undervalued.

Insider Buying and Selling at United Therapeutics

In other news, CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction on Monday, August 31st. The stock was sold at an average price of $511.09, for a total transaction of $4,855,355.00. Following the sale, the chief executive officer owned 324,443 shares in the company, valued at $165,819,572.87. This trade represents a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last 90 days, insiders sold 412,238 shares of company stock worth $220,071,746. Corporate insiders own 8.60% of the company’s stock.

Institutional Trading of United Therapeutics

A number of hedge funds have recently added to or reduced their stakes in UTHR. BlackRock Inc. purchased a new stake in United Therapeutics in the 2nd quarter valued at about $2,868,735,000. Janus Henderson Group PLC boosted its position in shares of United Therapeutics by 8.9% in the first quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock worth $514,016,000 after acquiring an additional 70,829 shares during the last quarter. Jupiter Topco LLC acquired a new stake in shares of United Therapeutics in the second quarter worth approximately $450,140,000. First Trust Advisors LP grew its holdings in United Therapeutics by 23.5% in the first quarter. First Trust Advisors LP now owns 270,578 shares of the biotechnology company’s stock valued at $160,447,000 after purchasing an additional 51,555 shares during the period. Finally, Bank of New York Mellon Corp purchased a new stake in United Therapeutics in the second quarter valued at approximately $159,522,000. 94.08% of the stock is owned by institutional investors and hedge funds.

Key United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: HC Wainwright initiated coverage with a Buy rating and a $660 price target, implying roughly 12% upside from the cited share price. HC Wainwright ratings
• Neutral Sentiment: The company announced participation in November investor conferences, giving investors an opportunity to hear updates but not signaling a specific business development. Investor conference announcement
• Neutral Sentiment: A report listed short interest at zero shares. That figure suggests no reported short position, but offers little clear directional signal for the stock.
• Negative Sentiment: CEO Martine Rothblatt sold shares in multiple transactions on November 6 and 9, while director Christopher Patusky also sold shares on November 9. Insider sales can raise concern about sentiment, though they do not necessarily indicate a change in the company’s outlook. SEC filing

About United Therapeutics

United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma. Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.